Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Ironwood Pharma (IRWD) Stock Price & Analysis
210 Followers
IRWD Stock Chart & Stats
Day’s Range$7.64 - $7.94
52-Week Range― - ―
Previous Close$7.89
Volume1.34M
Average Volume (3M)N/A
Market Cap
$1.19B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$0.2Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding156,528,648
10 Day Avg. Volume2,371,180
30 Day Avg. Volume4,669,921
Standard Deviation0.11
R-Squared0.07
Alpha-0.00771
Financial Highlights & Ratios
Price to Book (P/B)-3.48
Price to Sales (P/S)2.79
Price to Cash Flow (P/CF)8.50
P/FCF Ratio8.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside134.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ironwood Pharma News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPhase 3 top line data for apraglutide met the primary endpoint and showed efficacy in reducing parenteral support volume, highlighting its potential as a beneficial treatment option.
Market PotentialWith the strong sales force and the potential to tap into a billion-dollar market, Ironwood Pharmaceuticals' apraglutide presents a significant opportunity for growth in treating gastrointestinal diseases.
Safety ProfilePositive results from the exploratory Phase 2 STARGAZE trial for apraglutide indicate a favorable safety and tolerability profile, a crucial factor for patient acceptance and continued use.
Bears Say
Clinical Trial OutcomesApra did not reach statistical significance with other key secondary endpoints in colon-in-continuity patients.
Financial PerformancePrice erosion due to the removal of the Medicaid AMP cap poses a near-term headwind for Linzess revenue sales.
Market ExpectationsLack of differentiation could cause the stock to be flat to down 20% from current levels.
---
Ownership Overview
24.91% Insiders
30.24% Mutual Funds
36.74% Other Institutional Investors
8.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Currently, no data Available
What is Ironwood Pharma’s market cap?
Currently, no data Available
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Feb 15, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.2 by -$0.21.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.29 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is $0.2.
How many shares outstanding does Ironwood Pharma have?
Currently, no data Available
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.2. Following the earnings report the stock price went down -2.977%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is Driehaus Capital Management LLC. It holds Ironwood Pharma’s shares valued at 18M.
---
Ironwood Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (134.68% Upside)
$18.00 (134.68% Upside)
Blogger Sentiment
Bullish
IRWD Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.20%
12-Months-Change
Fundamentals
Return on Equity
-654.88%
Trailing 12-Months
Asset Growth
-57.20%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q4 2024
0:00 / 0:00
---
IRWD Stock 12 Months Forecast
Average Price Target
$18.00
▲(134.68% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Bausch Health Companies
―
Catalyst Pharma
―
Eagle Pharmaceuticals
―
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+12.52%
reiterated a buy rating 21 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.52% per trade.
---